Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 15/20 | 0.79 |
| ▸ | JAK1 | P23458 | 13/20 | 0.79 |
| ▸ | JAK2 | O60674 | 7/20 | 0.79 |
| ▸ | BRD4 | O60885 | 7/20 | 0.79 |
| ▸ | RET | P07949 | 4/20 | 0.79 |
| ▸ | TYK2 | P29597 | 4/20 | 0.79 |
| ▸ | FLT3 | P36888 | 4/20 | 0.79 |
| ▸ | BTK | Q06187 | 4/20 | 0.79 |
| ▸ | SYK | P43405 | 4/20 | 0.79 |
| ▸ | EGFR | P00533 | 3/20 | 0.79 |
| ▸ | PLK4 | O00444 | 3/20 | 0.79 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.79 |
| ▸ | AURKA | O14965 | 3/20 | 0.79 |
| ▸ | DCLK1 | O15075 | 3/20 | 0.79 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.79 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.79 |
| ▸ | PAK4 | O96013 | 3/20 | 0.79 |
| ▸ | ABL1 | P00519 | 3/20 | 0.79 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.79 |
| ▸ | INSR | P06213 | 3/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30381504 | 1.00 | JAK3 (0.79) | JAK3JAK1JAK2BRD4RET | |
| SCHEMBL20285974 | 0.92 | JAK2 (0.81) | JAK3JAK1JAK2BRD4RET | |
| SCHEMBL28489539 | 0.92 | BRD4 (0.81) | JAK3JAK1JAK2BRD4RET | |
| SCHEMBL20330039 | 0.92 | BRD4 (0.82) | JAK3JAK1JAK2BRD4RET | |
| SCHEMBL16985210 | 0.91 | BRD4 (0.84) | JAK3JAK1JAK2BRD4RET | |
| Fedratinib SCHEMBL29351417 | 0.89 | BRD4 (1.00) | JAK3JAK1JAK2BRD4RET | |
| Fedratinib SCHEMBL263741 | 0.89 | BRD4 (1.00) | JAK3JAK1JAK2BRD4RET | |
| Fedratinib SCHEMBL2734027 | 0.88 | BRD4 (0.98) | JAK3JAK1JAK2BRD4RET | |
| SCHEMBL13868200 | 0.88 | BRD4 (0.79) | JAK3JAK1JAK2BRD4RET | |
| Fedratinib SCHEMBL21773035 | 0.87 | BRD4 (0.91) | JAK3JAK1JAK2BRD4RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3927704-A1 | CRYSTALLINE FORMS OF A JAK2 INHIBITOR | Impact Biomedicines, Inc. (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-3923948-A1 | CRYSTALLINE FORMS OF A JAK2 INHIBITOR | Impact Biomedicines, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| WO-2020167844-A1 | CRYSTALLINE FORMS OF A JAK2 INHIBITOR | IMPACT BIOMEDICINES, INC. (US) | 2020-08-20 | — | — | WO | disclosed |
| WO-2020167845-A1 | CRYSTALLINE FORMS OF A JAK2 INHIBITOR | IMPACT BIOMEDICINES, INC. (US) | 2020-08-20 | — | — | WO | disclosed |
| WO-2019173224-A1 | DEUTERATED COMPOUNDS AND CHIMERAS AND USES THEREOF | BIOTHERYX, INC. (US) | 2019-09-12 | — | — | WO | disclosed |
| US-10040804-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| EP-1951684-B1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2016-07-13 | — | — | EP | disclosed |
| EP-1951684-B1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-8604042-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| WO-2007053452-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | JAK3 3/4885JAK1 4/4885JAK2 1/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | JAK3 3/4885JAK1 4/4885JAK2 1/4885 |
| US-10040804-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | JAK3 231/4885JAK1 39/4885JAK2 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.